Intrivo is a digital health company whose mission is to help people live happier, healthier and longer lives by providing them with intuitive tools and comprehensive health information to steward them across their entire health journey. In the midst of the current COVID-19 pandemic, we’ve been focused on helping companies reopen the economy, and individuals rediscover and reconnect through the use of rapid tests. We are the exclusive U.S. commercialization partner to Access Bio, an innovative diagnostics company that has received EUA approval for their CareStart™ COVID-19 Antigen test (as well as the CareStart PCR and Antibody tests).
Public
Sector
Sector
K-12 Education
Higher Education
State & Local Government
Protect your teams with a simple, affordable and integrated health control solutions with Intrivo Diagnostics, available on a cooperative contract through OMNIA Partners.
Intrivo Diagnostics, Inc Contract Documentation
U.S. Communities, National IPA, & NCPA are wholly-owned subsidiaries of OMNIA Partners, dba OMNIA Partners, Public Sector. All public sector participants already registered with National IPA, U.S. Communities, or NCPA continue to have access to all contracts, with certain exceptions, in the portfolio and do not need to re-register to use a legacy National IPA, legacy U.S. Communities, legacy NCPA, or new OMNIA Partners contract. U.S. Communities, National IPA, and NCPA remain separate legal entities and lead agency contracts completed under each brand are effective and available for use through the contract’s approved term. In the event we believe re-registration is necessary for any reason, OMNIA Partners will let you know.
Digital Healthcare Diagnostic Testing and Related Products and Services
Region 14 ESC - TX
Contract Number: 09-11
Initial Term: December 13, 2021 through December 31, 2024
Renewal Options: Option to renew for two (2) additional one-year periods through December 31, 2026